Befotertinib

CAS No. 1835667-63-4

Befotertinib( D-0316 )

Catalog No. M28217 CAS No. 1835667-63-4

Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 235 In Stock
5MG 187 In Stock
10MG 297 In Stock
25MG 525 In Stock
50MG 732 In Stock
100MG 1004 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Befotertinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
  • Description
    Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    D-0316
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    CDK2|CDK5
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1835667-63-4
  • Formula Weight
    567.61
  • Molecular Formula
    C29H32F3N7O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (88.09 mM)
  • SMILES
    C=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(CC(F)(F)F)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(C)CCN(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ka?mierczak A, et al. A novel mechanism of non-Aβ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). Neurochem Int. 2011;58(2):206-214.
molnova catalog
related products
  • Mutated EGFR-IN-1

    Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.

  • CHMFL-EGFR-202

    CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).

  • CP-380736

    CP-380736 is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a tyrosine kinase that activates MAPK, JNK, and Akt pathways, and is an important mediator of several types of cancer.